ADHD and periods: The hidden link reshaping UK women’s health

The study that could change how we see ADHD

For decades, ADHD has been framed as a condition of restless boys and distracted men. But a first-of-its-kind study by researchers at King’s College London is challenging that narrative, revealing how menstrual cycles may intensify symptoms for women with the disorder. The findings, published last month in the Journal of Psychiatric Research, suggest that hormonal fluctuations during the luteal phase—just before menstruation—can exacerbate impulsivity, emotional dysregulation, and cognitive fog in women with ADHD.

The study, which tracked 200 women over six months, found that 78% reported a noticeable worsening of symptoms in the week leading up to their period. For some, this meant heightened anxiety; for others, an inability to focus at work or manage daily tasks. "We’re seeing a pattern that’s been overlooked for too long," said Dr. Jessica Agnew-Blais, the lead researcher. "ADHD in women is often misdiagnosed or dismissed as mood swings, but what we’re documenting is a physiological link between hormonal cycles and neurological symptoms."

The implications are far-reaching. In the UK, where ADHD diagnoses in women have risen by 400% over the past decade, the study could force a reckoning with how the condition is treated—and who gets access to care. Currently, women wait an average of 3.5 years for an ADHD assessment on the NHS, compared to 18 months for men. Campaigners argue that the new research underscores the need for gender-specific guidelines, including routine screening for hormonal influences during diagnosis.

The workplace blind spot

The study’s findings arrive as UK employers face growing pressure to accommodate neurodivergent workers. A 2025 report by the Chartered Institute of Personnel and Development (CIPD) found that 62% of women with ADHD had left or considered leaving a job due to a lack of support. Yet only 14% of companies have policies addressing menstrual health in the workplace.

For women like Sarah Whitaker, a 32-year-old marketing manager in Manchester, the link between her cycle and ADHD symptoms was a revelation. "I’d always assumed my ‘off weeks’ were just burnout," she said. "But tracking my symptoms alongside my period made it clear—my brain chemistry changes. My manager thought I was being inconsistent; now I wonder if she’d have been more understanding if I’d had a diagnosis."

The disconnect highlights a broader issue: while menstrual health has gained visibility in recent years—thanks in part to campaigns around period poverty and menopause—its intersection with neurodiversity remains largely unaddressed. "We’re still treating women’s health as a series of silos," said Dr. Agnew-Blais. "But the body doesn’t work that way. Hormones affect everything from mood to memory, and for women with ADHD, that impact is amplified."

Some companies are beginning to take notice. Last year, the law firm Clifford Chance introduced "neurodiversity leave," allowing employees with ADHD or autism to take paid time off during symptom flare-ups. But such policies remain rare. "Most employers don’t even recognise menstrual health as a workplace issue," said Kate Sang, a professor of gender and employment studies at Heriot-Watt University. "Adding ADHD to the equation makes it even more complex—and even more necessary."

The NHS at a crossroads

The study also raises uncomfortable questions about the NHS’s ability to meet the needs of women with ADHD. With waiting lists for assessments stretching to five years in some regions, many women are turning to private clinics, where costs can exceed £1,000. For those who can’t afford it, the consequences are severe: a 2026 survey by the ADHD Foundation found that 30% of undiagnosed women had been misdiagnosed with depression or anxiety, leading to years of ineffective treatment.

The issue is particularly acute for women from marginalised backgrounds. Black and minority ethnic women are 40% less likely to receive an ADHD diagnosis than their white counterparts, despite reporting similar symptoms. "There’s a layering of biases here," said Dr. Tony Lloyd, CEO of the ADHD Foundation. "Women’s pain is often dismissed, and when you add race or class into the mix, it becomes even harder to get heard."

The NHS has pledged to reduce waiting times, but progress has been slow. In the meantime, grassroots organisations like ADHD Women’s Palooza are filling the gap, offering peer support and advocacy. "The system is broken," said founder Linda Roggli. "But women are finding each other. That’s how change happens—from the ground up."

What’s next?

The King’s College study is just the beginning. Researchers are now exploring whether hormonal treatments, such as birth control or progesterone therapy, could mitigate ADHD symptoms in women. Early results are promising, but the field remains underfunded. "We’re playing catch-up," admitted Dr. Agnew-Blais. "For too long, women’s health has been an afterthought in medical research. That’s starting to change, but we need more data—and more urgency."

For women like Whitaker, the study offers validation. "It’s not ‘all in my head,’" she said. "It’s real, it’s measurable, and it deserves to be taken seriously." As the UK grapples with a mental health crisis and a workforce struggling to adapt, the question is whether institutions will listen—or continue to treat women’s health as an optional extra.